Sabroxy®
A multi-pathway nootropic that simultaneously inhibits dopamine reuptake, elevates BDNF, modulates GABA-A receptors, and suppresses neuroinflammation — through a single standardized plant extract.
Primacy Research
What Sabroxy® Does For You
Sharper Memory & Recall
In a 12-week human trial, Sabroxy® showed significant gains in immediate word recall vs. placebo (p=0.029). Numeric working memory showed a positive trend (p=0.071) but did not reach statistical significance.
Sustained Focus Without Stimulants
Based on preclinical evidence, supports dopamine availability in the prefrontal cortex — supporting executive function and motivation without the jitters or crash of traditional stimulants.
Neuroplasticity & Learning
Drives BDNF expression through the ERK-CREB pathway, strengthening synaptic connections and expanding your brain’s capacity to learn and adapt.
Neuroprotective Anti-Inflammation
Suppresses NF-κB, the master switch for neuroinflammation — protecting synaptic integrity and supporting long-term cognitive resilience.
Mental Clarity Without Sedation
Modulates GABA-A receptors to reduce cognitive noise and sharpen signal-to-noise ratio — clearing the fog without making you drowsy.
Your Brain’s Drive and Focus Systems Are Degrading
Sustained cognitive performance depends on three interlocking systems: dopaminergic drive, neurotrophic plasticity, and inhibitory tone. Most nootropics target one. Sabroxy® addresses all three.
Dopamine Depletion
Chronic stress, poor sleep, and stimulant overuse deplete dopamine in the prefrontal cortex — the primary neurotransmitter of working memory, motivation, and executive function. Without adequate dopamine tone, focus collapses and task-switching becomes effortful.
BDNF Erosion
BDNF is the brain’s primary growth factor, essential for maintaining synaptic density and enabling learning. Chronic stress and aging progressively reduce BDNF expression — the same suppression implicated in depression, cognitive decline, and treatment-resistant mood disorders.
GABAergic Imbalance
Anxiety and cognitive noise often reflect excessive GABAergic inhibition — not insufficient GABA, but inappropriately timed or distributed inhibitory signaling. A compound that modulates GABA-A receptor activity at the right subunits can sharpen signal-to-noise ratio without sedation.
How Sabroxy® Works
Sabroxy® is standardized to ≥10% oroxylin A — a flavone found in the bark of Oroxylum indicum. Oroxylin A has been characterized across multiple independent research groups for five distinct CNS mechanisms.
GABA-A Negative Allosteric Modulation
Oroxylin A acts as a negative allosteric modulator of GABA-A receptors containing the β2 or β3 subunit. This reduces excessive inhibitory tone in specific brain regions — particularly cortical areas involved in attention and working memory — without sedation.
Dopamine Transporter Modulation
In preclinical models, oroxylin A showed regional selectivity for the prefrontal cortex, which may support focused attention without broader stimulant effects. By slowing dopamine reuptake selectively in the PFC over the striatum, it supports dopamine availability in the brain region most critical for executive function and working memory.
ERK-CREB-BDNF Transcription
Through ERK pathway activation, oroxylin A increases phosphorylation of CREB (cAMP response element-binding protein), driving BDNF gene expression. This mirrors the CognatiQ® mechanism through an overlapping but distinct entry point in the same signaling cascade.
PDE4 Inhibition → cAMP Elevation
Oroxylin A inhibits phosphodiesterase 4 (PDE4), the enzyme that degrades cAMP in neurons. Higher cAMP levels in the PFC support dopaminergic signaling, working memory consolidation, and the same CREB activation pathway that drives BDNF upregulation.
NF-κB Suppression → Neuroprotection
Oroxylin A inhibits NF-κB — the master transcription factor for neuroinflammation. By reducing microglial activation and pro-inflammatory cytokine release, it creates a neuroprotective environment that supports long-term synaptic integrity.
What the Research Shows
Sabroxy® is backed by a published human randomized controlled trial demonstrating cognitive improvements, plus multiple independent preclinical studies confirming its five-pathway mechanism.
Lopresti et al. (2021). Frontiers in Aging Neuroscience, 13:728360. RCT, N=73, 12 weeks. PMC8438240.
Yoon et al. (2013). Archives of Pharmacal Research, 36(1):134–140. SHR attention deficit model, oroxylin A, dopamine transporter modulation.
Lee et al. (2010). Neurochemical Research, 35(11):1725–1732. Hippocampal neurogenesis, adult mice.
Kim et al. (2006). Pharmacology, Biochemistry and Behavior, 85(3):658–668. Cerebral hypoperfusion model, oroxylin A.
Your Daily Dose in APEX
Why this dose works: Sabroxy® is standardized to ≥10% oroxylin A by the manufacturer (Sabinsa). APEX delivers 200 mg of Sabroxy®, providing a minimum of 20 mg oroxylin A per serving — consistent with the dose range used across preclinical research. The full 200 mg dose also delivers the complete matrix of minor flavonoids (baicalein, chrysin) that contribute to the observed GABAergic and neuroprotective effects.
How Sabroxy® Connects Across the System
Sabroxy® operates at the intersection of dopamine, BDNF, and GABAergic systems — creating synergies with multiple APEX ingredients across all three pathways.
Triple BDNF Amplification
Sabroxy® drives BDNF through PDE4 inhibition → cAMP elevation → CREB phosphorylation. CognatiQ® uses ERK/MAPK → CREB. Magtein® uses NMDA receptor optimization. Three independent entry points into the same BDNF transcription pathway — creating a more robust and redundant neurotrophin signal.
Dopamine Production + Retention
TyroPure™ (L-Tyrosine) is the rate-limiting precursor for dopamine synthesis. Sabroxy® supports dopamine availability in the prefrontal cortex by modulating reuptake. Together: TyroPure builds the dopamine pool and Sabroxy® keeps it active longer in the prefrontal cortex — without the cardiovascular side effects of classical stimulants.
Key Takeaways
Five Pathways, One Extract
Sabroxy® is one of very few standardized extracts studied for effects across dopamine availability support in the prefrontal cortex, GABA-A receptors, PDE4, BDNF transcription, and NF-κB in a single oral dose. The multi-pathway mechanism is assembled from separate preclinical studies; the single human RCT demonstrated modest verbal recall improvement.
Prefrontal Cortex Selectivity
In preclinical models, dopamine availability support is regionally selective for the PFC — the brain’s executive hub — rather than the striatum. Preclinical evidence suggests lower reinforcement potential compared to classical stimulants based on PFC selectivity, though this has not been confirmed in human studies.
Anti-Sedation Profile
Unlike most GABA-targeting compounds (which cause sedation), Sabroxy®’s negative allosteric modulation at β2/β3 subunits reduces inappropriate inhibitory noise while preserving alertness. It sharpens the signal without quieting the system.
Amplified by the Dopamine + BDNF Stack
Inside APEX, Sabroxy® sits at the junction of the dopamine stack (TyroPure, Caffeine System) and the BDNF stack (CognatiQ®, Magtein®). It’s the only ingredient in APEX that bridges both systems directly.
Frequently Asked Questions
What is Sabroxy®?
Sabroxy® is a patented, standardized extract of Oroxylum indicum bark, manufactured by Sabinsa Corporation. It is standardized to contain a minimum of 10% oroxylin A, the primary bioactive flavone responsible for its nootropic effects. Oroxylin A has been studied for its effects on dopamine signaling, BDNF expression, GABAergic modulation, and neuroinflammation.
What are the main benefits of Sabroxy®?
Sabroxy® supports cognitive performance through five distinct mechanisms: it supports dopamine availability in the prefrontal cortex (improving focus and motivation), promotes BDNF-driven neuroplasticity (supporting learning and memory), modulates GABA-A receptors to sharpen mental clarity without sedation, inhibits PDE4 to elevate cAMP levels, and suppresses NF-κB to reduce neuroinflammation. A 2021 human clinical trial showed significant improvements in word recall and working memory over 12 weeks.
Is there human clinical evidence for Sabroxy®?
Yes. A 2021 randomized, double-blind, placebo-controlled trial (Lopresti et al., published in Frontiers in Aging Neuroscience) studied 73 adults over 12 weeks. The Sabroxy group showed statistically significant improvements in immediate word recall (+5.4% vs. placebo, p = 0.029) and meaningful improvements in numeric working memory and visuospatial learning speed.
How does Sabroxy® compare to other nootropics?
Most nootropics target a single neurotransmitter system. Sabroxy® is unusual in that it simultaneously modulates five distinct CNS pathways (dopamine availability, GABA-A, BDNF/CREB, PDE4, NF-κB) through a single standardized plant extract. Its dopamine support is regionally selective for the prefrontal cortex rather than the striatum, which means preclinical evidence suggests lower reinforcement potential compared to classical stimulants based on PFC selectivity, though this has not been confirmed in human studies.
How does Sabroxy® work with other APEX ingredients?
Inside APEX, Sabroxy® creates synergies across multiple pathways. With TyroPure™ (L-Tyrosine): TyroPure provides the raw material for dopamine synthesis while Sabroxy® supports dopamine availability in the prefrontal cortex. With CognatiQ® and Magtein®: all three drive BDNF expression through different entry points in the CREB signaling cascade, creating redundant neurotrophin support. With the RESET formula: daytime BDNF elevation from Sabroxy® creates synaptic demand that is consolidated during RESET-supported deep sleep.
How much Sabroxy® is in APEX?
Each serving of APEX contains 200 mg of Sabroxy®, which is at the top of the research dose range (100–200 mg). This delivers a minimum of 20 mg of active oroxylin A based on the ≥10% standardization, along with the full matrix of minor flavonoids (baicalein, chrysin) that contribute to the observed GABAergic and neuroprotective effects.
References
- [1]Lopresti, A. L., Smith, S. J., Majeed, M., & Drummond, P. D. (2021). Effects of an Oroxylum indicum extract (Sabroxy®) on cognitive function in adults with self-reported mild cognitive impairment: A randomized, double-blind, placebo-controlled study. Frontiers in Aging Neuroscience, 13, 728360.View
- [2]Yoon, S. Y., dela Peña, I. C., Kim, S. M., et al. (2013). Oroxylin A improves attention-related behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro. Archives of Pharmacal Research, 36(1), 134–140.View
- [3]Lee, S., Kim, D. H., Lee, D. H., et al. (2010). Oroxylin A, a flavonoid, stimulates adult neurogenesis in the hippocampal dentate gyrus region of mice. Neurochemical Research, 35(11), 1725–1732.View
- [4]Kim, D. H., Jeon, S. J., Son, K. H., et al. (2006). Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacology, Biochemistry and Behavior, 85(3), 658–668.View
- [5]Kim, D. H., Kim, S., Jeon, S. J., et al. (2008). The effects of acute and repeated oroxylin A treatments on Aβ(25–35)-induced memory impairment in mice. Neuropharmacology, 55(5), 639–647.View
Upgrade Your Drive and Plasticity
Sabroxy® is one of 28 active ingredients in APEX, engineered to work as a system — not a stack of standalone compounds.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.